MEET QPS AT THE WORLDSymposium™ 2024; February 4 - 9, SAN DIEGO, CALIFORNIA, USA

Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis

TDP-43 Induced ALS Mouse Model

The TAR DNA binding protein (TARDBP or TDP-43) is shown to play a crucial role in a growing set of neurodegenerative diseases. While strongly related to sporadic and familial forms of amyotrophic lateral sclerosis (ALS), intraneuronal TDP-43 accumulation and aggregation is also related to frontotemporal lobar degeneration (FTLD-TDP or formerly FTLD-U).

To induce ALS in C57BL/6 mice, animals are injected into the motor cortex with adeno-associated viral (AAV) particles of serotype 9 that express human TDP-43 (AAV9-GFP-hTDP-43). Control animals are injected with AAV9-GFP. Analyzing the animals which were induced at 3 months of age and followed over the next 6 months, the AAV9-GFP-hTDP-43 injected animals show:

  • Early muscle weakness
  • Learning deficits
  • hTDP-43 expression in cortex
  • Increased activated microglia
  • Increased ubiquitination
  • Neuronal loss

Muscle weakness can be observed already 3 months after AAV9-GFP-hTDP-43 injection (Figure 1).

wire hanging

Figure 1: Wire hanging in AAV9-GFP-hTDP-43 and control mice. Latency to hang on the wire up to 300 s was measured. Two-Way-ANOVA with Bonferroni post hoc test. Mean + SEM. Control: n = 16, hTDP-43: n = 20. * p < 0.05, ** p < 0.01, *** p < 0.001.

Six months after AAV9-GFP-hTDP-43 injection, mice express hTDP-43 protein in the cortex (Figure 2).

TDP43

Figure 2: Expression of human and total TDP-43 in the cortex of control and hTDP-43 mice. Western blot analysis of cortex samples of AAV9-GFP-hTDP-43 and control mice 6 months after injection, homogenized in RIPA buffer and with GAPDH as loading control. PC: positive control = hippocampal RIPA sample of transgenic TDP-43 mouse. NC: negative control = untreated wild type mouse.

hTDP-43 expression and increased levels of activated microglia are measurable in the brain of AAV9-GFP-hTDP-43-injected mice after 6 months (Figure 3).

TDP43

Figure 3: Immunolabeling of GFP (white), human TDP-43 (red), Iba1 (microglia marker, green) and nuclei (DAPI, blue) in the brain of control mice (A) and AAV9-GFP-hTDP-43 injected (B). Coronally cut brain samples at 0.62 mm. White box: Area of injection magnified on the right. The virus was injected bilaterally into the motor cortex region M1 of 3 months old mice. Samples were collected 6 months after injection.

QPS Neuropharmacology offers a custom-tailored study design for the induced ALS model, and we are flexible to accommodate your special interest. We are also happy to advise you and propose study designs. Virally induced hTDP-43 mice are a valuable model of slowly progressing ALS. Vehicle-injected wild type mice can serve as control needed for proper study design. This model is therefore a proper model to evaluate the efficacy of potential treatments against ALS and to observe the time dependent effects of such a treatment.

We are happy to evaluate the efficacy of your compound in an induced ALS animal model! The most common readouts include:

You might also be interested in these related topics:

We are happy to receive your inquiry.

In Vitro Services

QPS Neuropharmacology provides research services with numerous standardized cell culture systems including transgenic and non-transgenic cell lines, glial cells, primary chicken and rat peripheral and central nervous system neurons of different developmental stages and organotypic brain slices. New models are developed and validated on request.
LEARN MORE

In Vivo Services

As a leading CRO for CNS drug development, QPS Neuropharmacology is the premier provider for services with transgenic animals. We have more than 20 years of experience in generating, characterizing, and maintaining transgenic disease models and applying them for drug testing projects.
LEARN MORE

Ex Vivo Services

QPS Neuropharmacology's expertise lies within the field of neurodegenerative diseases. We provide a state of the art research environment (AAALAC certified) for testing and evaluating new potential treatment approaches.
LEARN MORE

Biobank

QPS Neuropharmacology's well characterized and validated in vivo models are useful tools to push your CNS drug discovery research forward. We are happy to support your research activities with sample material from our biobank composed of various specimen derived from our in-house in vivo models.
LEARN MORE

animal models

QPS Neuropharmacology is highly experienced in generating, characterizing, and maintaining transgenic disease models and using them for drug testing projects for more than 20 years.
LEARN MORE

behavioral testing

QPS Neuropharmacology provides a wide range of behavioral tests for various indications. Most tests are evaluated using rater-independent digital animal tracking systems.
LEARN MORE

histology services

QPS Neuropharmacology offers a full set of histology services ranging from collection of tissue samples to delivering study reports that contain all experimental procedures and their outcome.
LEARN MORE

biomarkers

QPS Neuropharmacology Department of Translational Medicine offers a selection of molecular biological methods for the investigation of various diseases. The unit supports in vitro and in vivo studies performed at QPS Austria.
LEARN MORE